JP2024534545A5 - - Google Patents
Info
- Publication number
- JP2024534545A5 JP2024534545A5 JP2024518144A JP2024518144A JP2024534545A5 JP 2024534545 A5 JP2024534545 A5 JP 2024534545A5 JP 2024518144 A JP2024518144 A JP 2024518144A JP 2024518144 A JP2024518144 A JP 2024518144A JP 2024534545 A5 JP2024534545 A5 JP 2024534545A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- fragment
- acid sequence
- immune complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026020040A JP2026097838A (ja) | 2021-09-22 | 2026-02-10 | インターロイキン２変異体およびその融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111110032 | 2021-09-22 | ||
| CN202111110032.3 | 2021-09-22 | ||
| PCT/CN2022/120265 WO2023045977A1 (zh) | 2021-09-22 | 2022-09-21 | 白介素2突变体以及其融合蛋白 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026020040A Division JP2026097838A (ja) | 2021-09-22 | 2026-02-10 | インターロイキン２変異体およびその融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534545A JP2024534545A (ja) | 2024-09-20 |
| JP2024534545A5 true JP2024534545A5 (enExample) | 2025-11-11 |
| JP7864826B2 JP7864826B2 (ja) | 2026-05-25 |
Family
ID=85720093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518144A Active JP7864826B2 (ja) | 2021-09-22 | 2022-09-21 | インターロイキン２変異体およびその融合タンパク質 |
| JP2026020040A Pending JP2026097838A (ja) | 2021-09-22 | 2026-02-10 | インターロイキン２変異体およびその融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026020040A Pending JP2026097838A (ja) | 2021-09-22 | 2026-02-10 | インターロイキン２変異体およびその融合タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240391973A1 (enExample) |
| EP (1) | EP4406965A4 (enExample) |
| JP (2) | JP7864826B2 (enExample) |
| KR (1) | KR20240082364A (enExample) |
| CN (1) | CN118119635A (enExample) |
| AU (2) | AU2022350407B2 (enExample) |
| CA (1) | CA3233075A1 (enExample) |
| CL (1) | CL2024000834A1 (enExample) |
| CO (1) | CO2024004910A2 (enExample) |
| IL (1) | IL311643A (enExample) |
| MX (1) | MX2024003535A (enExample) |
| PE (1) | PE20241994A1 (enExample) |
| TW (1) | TWI858393B (enExample) |
| WO (1) | WO2023045977A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105634B (zh) | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| KR20220155316A (ko) * | 2020-03-19 | 2022-11-22 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 인터루킨-2 돌연변이 및 이의 용도 |
| WO2025007037A1 (en) * | 2023-06-28 | 2025-01-02 | Dragonfly Therapeutics, Inc. | Variant il-2 proteins |
| WO2025031434A1 (zh) * | 2023-08-08 | 2025-02-13 | 北京志道生物科技有限公司 | 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途 |
| AU2024411090A1 (en) | 2023-12-28 | 2026-07-16 | Fortvita Biologics (Singapore) Pte. Ltd. | Pd-1/il-2r bispecific antibody fusion protein, and use and usage method thereof |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| CN118373896B (zh) * | 2024-04-19 | 2025-07-29 | 上海科棋药业科技有限公司 | 抗pd-1抗体与il-2突变体的双功能融合蛋白 |
| WO2025252212A1 (zh) * | 2024-06-07 | 2025-12-11 | 福佑泰生物制药公司 | 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用 |
| WO2026012466A1 (en) * | 2024-07-12 | 2026-01-15 | Vibrant Pharma Limited | Interleukin-2 muteins and uses thereof |
| CN118546233B (zh) * | 2024-07-30 | 2024-10-18 | 成都微芯新域生物技术有限公司 | 白介素-21突变体及其应用 |
| WO2026083295A1 (en) * | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| CN121293311B (zh) * | 2025-08-01 | 2026-07-24 | 合肥天港免疫药物有限公司 | Il-2变体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| NZ234674A (en) * | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| JP7765181B2 (ja) * | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| CN111868079B (zh) * | 2017-12-27 | 2025-06-17 | 协和麒麟株式会社 | Il-2变体 |
| CN112105634B (zh) * | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| CA3143034A1 (en) * | 2019-06-14 | 2020-12-17 | Cugene Inc. | Novel interleukin-2 variants for the treatment of cancer |
| WO2020252421A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
| KR20220155316A (ko) * | 2020-03-19 | 2022-11-22 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 인터루킨-2 돌연변이 및 이의 용도 |
| WO2021185362A1 (zh) * | 2020-03-19 | 2021-09-23 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
-
2022
- 2022-09-21 JP JP2024518144A patent/JP7864826B2/ja active Active
- 2022-09-21 WO PCT/CN2022/120265 patent/WO2023045977A1/zh not_active Ceased
- 2022-09-21 PE PE2024000528A patent/PE20241994A1/es unknown
- 2022-09-21 CA CA3233075A patent/CA3233075A1/en active Pending
- 2022-09-21 IL IL311643A patent/IL311643A/en unknown
- 2022-09-21 AU AU2022350407A patent/AU2022350407B2/en active Active
- 2022-09-21 US US18/693,453 patent/US20240391973A1/en active Pending
- 2022-09-21 TW TW111135759A patent/TWI858393B/zh active
- 2022-09-21 KR KR1020247013147A patent/KR20240082364A/ko active Pending
- 2022-09-21 EP EP22872023.1A patent/EP4406965A4/en active Pending
- 2022-09-21 MX MX2024003535A patent/MX2024003535A/es unknown
- 2022-09-21 CN CN202280063868.9A patent/CN118119635A/zh active Pending
-
2024
- 2024-03-21 CL CL2024000834A patent/CL2024000834A1/es unknown
- 2024-04-18 CO CONC2024/0004910A patent/CO2024004910A2/es unknown
-
2025
- 2025-10-31 US US19/376,374 patent/US20260053898A1/en active Pending
- 2025-12-04 AU AU2025275202A patent/AU2025275202A1/en active Pending
-
2026
- 2026-02-10 JP JP2026020040A patent/JP2026097838A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021507698A5 (enExample) | ||
| JP2023085476A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2019533441A5 (enExample) | ||
| JP2022551969A5 (enExample) | ||
| JP2019502712A5 (enExample) | ||
| JP2025016538A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| JP2023516195A5 (enExample) | ||
| IL269395B2 (en) | Immunoconjugation of anti-PD-1 antibody with IL-2 or IL-15 mutation | |
| FI3606955T3 (fi) | Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita | |
| JP2018522541A5 (enExample) | ||
| JP2023554500A5 (enExample) | ||
| IL272747B1 (en) | Bispecific antibodies 1 + 2 | |
| JP2021533159A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| JP2017537896A5 (enExample) | ||
| EP3174897A1 (en) | Multispecific antibodies | |
| JP2024520666A5 (enExample) | ||
| JP2025038088A5 (enExample) | ||
| Acheampong | Bispecific antibody (bsAb) construct formats and their application in cancer therapy | |
| JP2023501276A5 (enExample) | ||
| JP2025506341A5 (enExample) | ||
| JPWO2022102768A5 (enExample) |